The US Food and Drug Administration's oncology center intends to leverage datasets from cancer studies interrupted by the COVID-19 pandemic to advance the use of decentralized clinical trial approaches.
The Oncology Center of Excellence is requesting that applicants submitting data in support of new drug applications or biologic license applications voluntarily add flags to distinguish between
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?